Rocket Pharmaceuticals (RCKT) Stock: Buy, Sell, or Hold?
RCKT - Rocket Pharmaceuticals, Inc. Common Stock
$2.21
-0.09 (-3.91%)
▼
5d:
-12.82%
30d:
-35.19%
90d:
-35.19%
WAIT
LOW Confidence
Analysis Updated: Oct 14, 2026 12:00 AM ET
Earnings: Nov 05, 2026
20d
Get Alerted When RCKT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: RCKT is down 12.8% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: RCKT is down 12.8% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: RCKT is currently trading at $2.21, which is considered oversold relative to its 30-day fair value range of $2.47 to $3.39.
Technical Outlook: Technically, RCKT is in a uptrend. The price is currently testing key support at $2.18. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.9% recently.
Market Sentiment: RCKT scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $8.58 (+288.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, RCKT is in a uptrend. The price is currently testing key support at $2.18. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.9% recently.
Market Sentiment: RCKT scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $8.58 (+288.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$2.47 -
$3.39
Company Quality Score
43/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
52.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.9%)
- BULLISH: Trading 288.2% below Wall St target ($8.58)
- WARNING: Composite score 43/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$2.47 -
$3.39
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$2.18
Resistance Level
$2.78
Current Trend
Uptrend
Technical data as of
Oct 14, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.70
Wall Street Target
$8.58
(+288.2%)
Share & Embed Analysis
Last updated: October 15, 2026 12:41 AM ET
Data refreshes hourly during market hours. Next update: 1:41 AM
Data refreshes hourly during market hours. Next update: 1:41 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is RCKT showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
VRDN
Viridian Therapeutics Inc |
STRONG BUY
17 analysts |
$37 | 66 BUY |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
20 analysts |
$36 | 48 HOLD |
|
MIRM
Mirum Pharmaceuticals Inc |
STRONG BUY
14 analysts |
$146 | 62 BUY |
|
SRRK
Scholar Rock Holding Corp |
STRONG BUY
18 analysts |
$70 | 44 HOLD |
|
PTGX
Protagonist Therapeutics… |
STRONG BUY
13 analysts |
$175 | 61 BUY |
